4D Molecular Therapeutics (FDMT) EBITDA Margin (2020 - 2026)
4D Molecular Therapeutics (FDMT) posted quarterly EBITDA Margin of 2416.15% for Q1 2026, up 38059100.0% year-over-year from N/an in Q1 2025, and down 14071.45% quarter-over-quarter from 17.29% in Q4 2025.
4D Molecular Therapeutics (FDMT) EBITDA Margin (2020 - 2026) Analysis & Trends
4D Molecular Therapeutics (FDMT) has reported EBITDA Margin for 7 consecutive years, with 2416.15% the latest figure, recorded in Q1 2026.
- In Q1 2026, EBITDA Margin rose 38059100.0% year-over-year to 2416.15%; the TTM figure through Mar 2026 stood at 203.47% (up 88382262.0% YoY), while the FY2025 annual figure was 187.24%, up 50749114.0% from the prior year.
- EBITDA Margin eased to 2416.15% in Q1 2026 per FDMT's latest filing, from 17.29% in the prior quarter.
- Across five years, EBITDA Margin topped out at 192905.26% in Q4 2023 and bottomed at 5611700.0% in Q4 2024.
- Historically, EBITDA Margin has averaged 529953.49% across 5 years, with a median of 13446.03% in 2023.
- Annual changes were most pronounced in 2024 — EBITDA Margin tumbled 580460526 bps — and 2025, when it soared 561171729 bps.
- 4D Molecular Therapeutics' EBITDA Margin stood at 2303.13% in 2022, then surged by 8476 bps to 192905.26% in 2023, then slumped by 3009 bps to 5611700.0% in 2024, then soared by 100 bps to 17.29% in 2025, then plunged by 14071 bps to 2416.15% in 2026.
- Business Quant data shows FDMT's EBITDA Margin at 2416.15% in Q1 2026, 17.29% in Q4 2025, and 67983.33% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 31.68% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 19.06% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -77,569,866.34% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.75% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 17.93% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.36% |
| 10 | 4D Molecular Therapeutics | 856.62 Mn | 495.28 Mn | - | -2,037.16% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -2,037.16% |
| Mar 31, 2026 | -2,416.15% |
| Dec 31, 2025 | 17.29% |
| Sep 30, 2025 | -67,983.33% |
| Jun 30, 2025 | -396,373.33% |
| Mar 31, 2025 | -383,007.14% |
| Dec 31, 2024 | -5,611,700.00% |
| Sep 30, 2024 | -1,704,400.00% |
| Jun 30, 2024 | -849,120.00% |
| Mar 31, 2024 | -136,200.00% |
| Dec 31, 2023 | 192,905.26% |
| Sep 30, 2023 | -69.16% |
| Jun 30, 2023 | -13,446.03% |
| Mar 31, 2023 | -10,102.68% |
| Dec 31, 2022 | -2,303.13% |
| Sep 30, 2022 | -5,299.00% |
| Jun 30, 2022 | -17,546.91% |
| Mar 31, 2022 | -2,165.05% |
| Dec 31, 2021 | -26,917.39% |
| Sep 30, 2021 | -1,658.93% |